Rituximab monotherapy as interim therapy in precursor B-ALL adults during peroids of hepatic toxicity: Report of two cases

Maya Koren-Michowitz; Naomi Rahimi-Levene; Yulia Volcheck; Izhar Hardan; Abraham Kornberg

doi:10.1002/ajh.20675

Rituximab monotherapy as interim therapy in precursor B-ALL adults during peroids of hepatic toxicity: Report of two cases

Maya Koren-Michowitz^*, Naomi Rahimi-Levene, Yulia Volcheck, Izhar Hardan, Abraham Kornberg

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Precursor B-ALL blasts may be positive for CD20 in up to 50% of cases. There are few reports on the use of the anti CD20 monoclonal antibody, rituximab, in children with B-ALL. We report on two adult patients with precursor B-ALL who developed significant hepatic toxicity during induction chemotherapy. Single agent rituximab was given until recovery of liver enzymes was established. Both patients were able to continue further chemotherapy, underwent an Allo BMT and are now 10-12 months after diagnosis in a continuous CR.

Original language	English
Pages (from-to)	979-980
Number of pages	2
Journal	American Journal of Hematology
Volume	81
Issue number	12
DOIs	https://doi.org/10.1002/ajh.20675
State	Published - Dec 2006
Externally published	Yes

Keywords

Hepatic toxicity
Precursor B-ALL
Rituximab

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/ajh.20675

Cite this

@article{5ebef2ab2ee44c55823f818d9015e592,

title = "Rituximab monotherapy as interim therapy in precursor B-ALL adults during peroids of hepatic toxicity: Report of two cases",

abstract = "Precursor B-ALL blasts may be positive for CD20 in up to 50% of cases. There are few reports on the use of the anti CD20 monoclonal antibody, rituximab, in children with B-ALL. We report on two adult patients with precursor B-ALL who developed significant hepatic toxicity during induction chemotherapy. Single agent rituximab was given until recovery of liver enzymes was established. Both patients were able to continue further chemotherapy, underwent an Allo BMT and are now 10-12 months after diagnosis in a continuous CR.",

keywords = "Hepatic toxicity, Precursor B-ALL, Rituximab",

author = "Maya Koren-Michowitz and Naomi Rahimi-Levene and Yulia Volcheck and Izhar Hardan and Abraham Kornberg",

year = "2006",

month = dec,

doi = "10.1002/ajh.20675",

language = "אנגלית",

volume = "81",

pages = "979--980",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "John Wiley and Sons Inc.",

number = "12",

}

TY - JOUR

T1 - Rituximab monotherapy as interim therapy in precursor B-ALL adults during peroids of hepatic toxicity

T2 - Report of two cases

AU - Koren-Michowitz, Maya

AU - Rahimi-Levene, Naomi

AU - Volcheck, Yulia

AU - Hardan, Izhar

AU - Kornberg, Abraham

PY - 2006/12

Y1 - 2006/12

N2 - Precursor B-ALL blasts may be positive for CD20 in up to 50% of cases. There are few reports on the use of the anti CD20 monoclonal antibody, rituximab, in children with B-ALL. We report on two adult patients with precursor B-ALL who developed significant hepatic toxicity during induction chemotherapy. Single agent rituximab was given until recovery of liver enzymes was established. Both patients were able to continue further chemotherapy, underwent an Allo BMT and are now 10-12 months after diagnosis in a continuous CR.

AB - Precursor B-ALL blasts may be positive for CD20 in up to 50% of cases. There are few reports on the use of the anti CD20 monoclonal antibody, rituximab, in children with B-ALL. We report on two adult patients with precursor B-ALL who developed significant hepatic toxicity during induction chemotherapy. Single agent rituximab was given until recovery of liver enzymes was established. Both patients were able to continue further chemotherapy, underwent an Allo BMT and are now 10-12 months after diagnosis in a continuous CR.

KW - Hepatic toxicity

KW - Precursor B-ALL

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=33845273871&partnerID=8YFLogxK

U2 - 10.1002/ajh.20675

DO - 10.1002/ajh.20675

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:33845273871

SN - 0361-8609

VL - 81

SP - 979

EP - 980

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 12

ER -

Rituximab monotherapy as interim therapy in precursor B-ALL adults during peroids of hepatic toxicity: Report of two cases

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this